Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Design of Safe Nanotherapeutics for the Excretion of Excess Systemic Toxic Iron.

Abbina S, Abbasi U, Gill A, Wong K, Kalathottukaren MT, Kizhakkedathu JN.

ACS Cent Sci. 2019 May 22;5(5):917-926. doi: 10.1021/acscentsci.9b00284. Epub 2019 Apr 11.

2.

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.

Kalathottukaren MT, Creagh AL, Abbina S, Lu G, Karbarz MJ, Pandey A, Conley PB, Kizhakkedathu JN, Haynes C.

Blood Adv. 2018 Aug 28;2(16):2104-2114. doi: 10.1182/bloodadvances.2016003616.

3.

Design of Polyphosphate Inhibitors: A Molecular Dynamics Investigation on Polyethylene Glycol-Linked Cationic Binding Groups.

Mafi A, Abbina S, Kalathottukaren MT, Morrissey JH, Haynes C, Kizhakkedathu JN, Pfaendtner J, Chou KC.

Biomacromolecules. 2018 Apr 9;19(4):1358-1367. doi: 10.1021/acs.biomac.8b00327. Epub 2018 Mar 23.

4.

Antimicrobial Peptide-Polymer Conjugates with High Activity: Influence of Polymer Molecular Weight and Peptide Sequence on Antimicrobial Activity, Proteolysis, and Biocompatibility.

Kumar P, Takayesu A, Abbasi U, Kalathottukaren MT, Abbina S, Kizhakkedathu JN, Straus SK.

ACS Appl Mater Interfaces. 2017 Nov 1;9(43):37575-37586. doi: 10.1021/acsami.7b09471. Epub 2017 Oct 19.

PMID:
29019386
5.

A Polymer Therapeutic Having Universal Heparin Reversal Activity: Molecular Design and Functional Mechanism.

Kalathottukaren MT, Abbina S, Yu K, Shenoi RA, Creagh AL, Haynes C, Kizhakkedathu JN.

Biomacromolecules. 2017 Oct 9;18(10):3343-3358. doi: 10.1021/acs.biomac.7b00994. Epub 2017 Sep 19.

PMID:
28880550
6.

Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Kalathottukaren MT, Haynes CA, Kizhakkedathu JN.

Drug Deliv Transl Res. 2018 Aug;8(4):928-944. doi: 10.1007/s13346-017-0413-4. Review.

PMID:
28741113
7.

Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

Kalathottukaren MT, Abraham L, Kapopara PR, Lai BF, Shenoi RA, Rosell FI, Conway EM, Pryzdial EL, Morrissey JH, Haynes CA, Kizhakkedathu JN.

Blood. 2017 Mar 9;129(10):1368-1379. doi: 10.1182/blood-2016-10-747915. Epub 2016 Dec 29.

8.

Advantages of replacing hydroxyethyl starch in University of Wisconsin solution with hyperbranched polyglycerol for cold kidney perfusion.

Li S, Constantinescu I, Guan Q, Kalathottukaren MT, Brooks DE, Nguan CY, Kizhakkedathu JN, Du C.

J Surg Res. 2016 Sep;205(1):59-69. doi: 10.1016/j.jss.2016.06.015. Epub 2016 Jun 15.

PMID:
27621000
9.

In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.

Hamilton JL, Imran Ul-Haq M, Abbina S, Kalathottukaren MT, Lai BF, Hatef A, Unniappan S, Kizhakkedathu JN.

Biomaterials. 2016 Sep;102:58-71. doi: 10.1016/j.biomaterials.2016.06.019. Epub 2016 Jun 10.

PMID:
27322959
10.

Toward Infection-Resistant Surfaces: Achieving High Antimicrobial Peptide Potency by Modulating the Functionality of Polymer Brush and Peptide.

Yu K, Lo JC, Mei Y, Haney EF, Siren E, Kalathottukaren MT, Hancock RE, Lange D, Kizhakkedathu JN.

ACS Appl Mater Interfaces. 2015 Dec 30;7(51):28591-605. doi: 10.1021/acsami.5b10074. Epub 2015 Dec 21.

PMID:
26641308
11.

Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.

Shenoi RA, Kalathottukaren MT, Travers RJ, Lai BF, Creagh AL, Lange D, Yu K, Weinhart M, Chew BH, Du C, Brooks DE, Carter CJ, Morrissey JH, Haynes CA, Kizhakkedathu JN.

Sci Transl Med. 2014 Oct 29;6(260):260ra150. doi: 10.1126/scitranslmed.3009427. Epub 2014 Oct 29.

12.

Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis.

Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH.

Blood. 2014 Nov 20;124(22):3183-90. doi: 10.1182/blood-2014-05-577932. Epub 2014 Sep 8.

Supplemental Content

Loading ...
Support Center